TRVI

Trevi Therapeutics recently reported that its Phase 2b CORAL trial of Haduvio (nalbuphine ER) in idiopathic pulmonary fibrosis-related chronic cough showed early, sustained improvements in patient-reported outcomes and was accepted for oral presentation at…

Trevi Therapeutics has delivered very strong long term gains, yet the stock now screens as expensive on broad valuation checks. This raises questions about how much of the story is already in the price.

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough

Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications.

Trevi Therapeutics Inc (TRVI) reports progress in IPF and RCC trials, backed by $319 million in funding and a competitive edge following a rival's program exit.

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth quarter of 2026 Management to host a conference call and webcast today at 4:30 p.m.

Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.

Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough.